Coenzyme M
- Generic Name
- Coenzyme M
- Brand Names
- Uromitexan
- Drug Type
- Small Molecule
- Chemical Formula
- C2H6O3S2
- CAS Number
- 3375-50-6
- Unique Ingredient Identifier
- VHD28S0H7F
- Background
Coenzyme M (commonly known by its salt form, Mesna) is a synthetic sulfhydryl (thiol) compound and is used for prophylaxis of Ifosfamide and cyclophosphamide induced hemorrhagic cystitis.
- Indication
Mesna is a uroprotective agent and is used prophylactically to reduce ifosfamide and cyclophosphamide induced hemorrhagic cystitis.
- Associated Conditions
- Hemorrhagic cystitis caused by cyclophosphamide, Hemorrhagic cystitis caused by ifosfamide
- Associated Therapies
- -
Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04881240
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
- Conditions
- Recurrent Chronic Myelomonocytic LeukemiaHematopoietic and Lymphoid Cell NeoplasmRecurrent Acute Myeloid LeukemiaRecurrent Acute Lymphoblastic LeukemiaRecurrent Myelodysplastic SyndromeRefractory Acute Lymphoblastic LeukemiaRefractory Acute Myeloid LeukemiaRefractory Chronic Myelomonocytic LeukemiaRefractory Myelodysplastic Syndrome
- Interventions
- First Posted Date
- 2021-02-12
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 17
- Registration Number
- NCT04752163
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
- Conditions
- Interventions
- Procedure: Biospecimen CollectionDrug: CarboplatinDrug: EtoposideBiological: FilgrastimDrug: IfosfamideProcedure: Magnetic Resonance ImagingDrug: MesnaBiological: PegfilgrastimProcedure: Peripheral Blood Stem Cell TransplantationOther: Questionnaire AdministrationRadiation: Radiation TherapyProcedure: Second-Look SurgeryDrug: Thiotepa
- First Posted Date
- 2020-12-24
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 160
- Registration Number
- NCT04684368
- Locations
- 🇺🇸
University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States
🇺🇸Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire, United States
🇦🇺Sydney Children's Hospital, Randwick, New South Wales, Australia
IS-free Treg HaploHCT
- Conditions
- Interventions
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT04678401
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
CD19 Targeted CAR T Cell Therapy in Patients With Relapsed/ Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
- First Posted Date
- 2020-12-04
- Last Posted Date
- 2021-03-19
- Lead Sponsor
- Sabz Biomedicals
- Target Recruit Count
- 22
- Registration Number
- NCT04653493
- Locations
- 🇮🇷
Gene therapy research center, Shariati hospital, Tehran university of medical sciences, Iran, Tehran, Iran, Islamic Republic of
🇮🇷Research Institute for Oncology- Hematology and Cell Therapy (RIOHCT), Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of
Haploidentical HCT for Severe Aplastic Anemia
- Conditions
- Interventions
- First Posted Date
- 2020-09-22
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 21
- Registration Number
- NCT04558736
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
- Conditions
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow Aspiration and BiopsyBiological: BlinatumomabDrug: DasatinibDrug: CyclophosphamideDrug: CytarabineDrug: DexamethasoneDrug: Doxorubicin HydrochlorideProcedure: Multigated Acquisition ScanProcedure: EchocardiographyDrug: Ponatinib HydrochlorideProcedure: ElectrocardiographyDrug: PrednisoneProcedure: Lumbar PunctureDrug: MethotrexateDrug: MesnaDrug: Vincristine Sulfate
- First Posted Date
- 2020-08-28
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 348
- Registration Number
- NCT04530565
- Locations
- 🇺🇸
Cancer Hematology Centers - Flint, Flint, Michigan, United States
🇺🇸University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
Cysteine-lowering Treatment With Mesna
- First Posted Date
- 2020-06-29
- Last Posted Date
- 2022-05-19
- Lead Sponsor
- University of Oslo
- Target Recruit Count
- 25
- Registration Number
- NCT04449536
- Locations
- 🇳🇴
University of Oslo, Oslo, Norway
CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)
- Conditions
- Interventions
- First Posted Date
- 2020-03-24
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT04318678
- Locations
- 🇺🇸
St Jude Children's Research Hospital, Memphis, Tennessee, United States
🇺🇸St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Stem Cell Transplantation in Crohn's Disease
- Conditions
- Interventions
- Drug: MesnaDrug: CyclophosphamideDrug: FilgrastimProcedure: Apheresis catheter placementProcedure: LeukapheresisDrug: FludarabineDrug: MethylprednisoloneDrug: DiphenhydramineDrug: AcetaminophenDrug: anti-thymocyte globulin (rabbit)Drug: lymphocyte immune globulinBiological: Peripheral Blood Stem Cell InfusionDrug: Cytoxan
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Cedars-Sinai Medical Center
- Target Recruit Count
- 15
- Registration Number
- NCT04224558
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.